980p 90.0 10.1%
Last Trade - 4:41pm
| Market Cap | ÂŁ641.1m |
| Enterprise Value | ÂŁ630.8m |
| Revenue | ÂŁn/a |
| Position in Universe | 516th / 1809 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 14.6 | 54.5 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Renalytix AI plc is an artificial intelligence-enabled in vitro diagnostics company. The Company’s diagnostic platform, KidneyIntelX, employs artificial intelligence-enabled algorithm that combines data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record (HER) systems, to generate a patient risk score. Its patient risk score enables prediction of progressive kidney function decline in chronic kidney disease (CKD), allowing physicians and healthcare systems to manage the allocation of treatments and clinical resources to patients. KidneyIntelX provides a reportable patient risk score integrated with specific guideline-driven clinical recommendations designed to manage patient treatment and compliance outcomes. The KidneyIntelX risk score is tied to specific clinical guideline recommendations developed by the healthcare system, health insurance providers or practice groups.
| Last Annual | June 30th, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | March 15, 2018 |
| Public Since | November 6, 2018 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Technology |
| Industry | Software & IT Services |
| Index | FTSE Aim All Share , FTSE Aim 100 , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 72,029,634 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Avon Hse 19 Stanwell Road, PENARTH, CF64 2EZ, United Kingdom |
| Web | https://renalytixai.com/ |
| Phone | +44 20 79338780 |
| Contact | () |
| Auditors | PKF Littlejohn LLP |
As of 4:41pm, shares in Renalytix AI are trading at 980p, giving the company a market capitalisation of ÂŁ641.1m. This share price information is delayed by 15 minutes.
Shares in Renalytix AI are currently trading at 980p and the price has moved by 0.174k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Renalytix AI price has moved by 0.160k% over the past year.
Of the analysts with advisory recommendations for Renalytix AI, there are there are currently 1 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Renalytix AI is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Renalytix AI is scheduled to issue upcoming financial results on the following dates:
Renalytix AI does not currently pay a dividend.
Renalytix AI does not currently pay a dividend.
Renalytix AI does not currently pay a dividend.
To buy shares in Renalytix AI you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Renalytix AI are currently trading at 980p, giving the company a market capitalisation of ÂŁ641.1m.
Here are the trading details for Renalytix AI:
Based on an overall assessment of its quality, value and momentum, Renalytix AI is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Renalytix AI are currently priced at 980p. At that level they are trading at 73.48% discount to the analyst consensus target price of 3,695.32.
Analysts covering Renalytix AI currently have a consensus Earnings Per Share (EPS) forecast of -0.2440535087 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Renalytix AI. Over the past six months, the relative strength of its shares against the market has been 41.94%. At the current price of 980p, shares in Renalytix AI are trading at 53.81% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Renalytix AI.
We were unable to find the directors for Renalytix AI.
Here are the top five shareholders of Renalytix AI based on the size of their shareholding:
